{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:15:27Z","timestamp":1793650527714,"version":"4.5.1"},"reference-count":323,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1038\/s41573-023-00735-0","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T11:02:29Z","timestamp":1689246149000},"page":"662-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Disease modification in inflammatory skin disorders: opportunities and challenges"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-3817","authenticated-orcid":false,"given":"Thomas","family":"Bieber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"735_CR1","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/jid.2013.446","volume":"134","author":"RJ Hay","year":"2014","unstructured":"Hay, R. J. et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J. Invest. Dermatol. 134, 1527\u20131534 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR2","doi-asserted-by":"crossref","unstructured":"Plewig, G., French, L. E., Ruzicka, T., Kaufman, R. & Hertl, M. Braun-Falco\u2019s Dermatology (Springer, 2022).","DOI":"10.1007\/978-3-662-63709-8"},{"key":"735_CR3","doi-asserted-by":"publisher","first-page":"737813","DOI":"10.3389\/fmed.2021.737813","volume":"8","author":"K Boch","year":"2021","unstructured":"Boch, K. et al. Lichen planus. Front. Med. 8, 737813 (2021).","journal-title":"Front. Med."},{"key":"735_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","volume":"8","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir, P. et al. Urticaria. Nat. Rev. Dis. Prim. 8, 61 (2022).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"735_CR5","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","volume":"149","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir, P. et al. Autoimmune chronic spontaneous urticaria. J. Allergy Clin. Immunol. 149, 1819\u20131831 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat, R. et al. Hidradenitis suppurativa. Nat. Rev. Dis. Prim. 6, 18 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"735_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke, W. H. & Schon, M. P. Psoriasis. Lancet 386, 983\u2013994 (2015).","journal-title":"Lancet"},{"key":"735_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","volume":"54","author":"C Conrad","year":"2018","unstructured":"Conrad, C. & Gilliet, M. Psoriasis: from pathogenesis to targeted therapies. Clin. Rev. Allergy Immunol. 54, 102\u2013113 (2018).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"735_CR9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/s41590-018-0256-2","volume":"19","author":"T Dainichi","year":"2018","unstructured":"Dainichi, T. et al. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nat. Immunol. 19, 1286\u20131298 (2018).","journal-title":"Nat. Immunol."},{"key":"735_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber, T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat. Rev. Drug Discov. 21, 21\u201340 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"735_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong, A. W. et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 156, 258\u2013269 (2020).","journal-title":"JAMA Dermatol."},{"key":"735_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger, S. & Novak, N. Atopic dermatitis. Lancet 387, 1109\u20131122 (2016).","journal-title":"Lancet"},{"key":"735_CR13","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S Stander","year":"2021","unstructured":"Stander, S. Atopic dermatitis. N. Engl. J. Med. 384, 1136\u20131143 (2021).","journal-title":"N. Engl. J. Med."},{"key":"735_CR14","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMra074081","volume":"358","author":"T Bieber","year":"2008","unstructured":"Bieber, T. Atopic dermatitis. N. Engl. J. Med. 358, 1483\u20131494 (2008).","journal-title":"N. Engl. J. Med."},{"key":"735_CR15","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E. & Barker, J. Psoriasis. Lancet 397, 1301\u20131315 (2021).","journal-title":"Lancet"},{"key":"735_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13671-017-0168-7","volume":"6","author":"YMF Andersen","year":"2017","unstructured":"Andersen, Y. M. F., Egeberg, A., Skov, L. & Thyssen, J. P. Comorbidities of atopic dermatitis: beyond rhinitis and asthma. Curr. Dermatol. Rep. 6, 35\u201341 (2017).","journal-title":"Curr. Dermatol. Rep."},{"key":"735_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaad.2017.08.002","volume":"78","author":"L Eckert","year":"2018","unstructured":"Eckert, L. et al. The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey. J. Am. Acad. Dermatol. 78, 54\u201361.e51 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/pde.13828","volume":"36","author":"JK Sandhu","year":"2019","unstructured":"Sandhu, J. K., Salame, N., Ehsani-Chimeh, N. & Armstrong, A. W. Economic burden of cutaneous infections in children and adults with atopic dermatitis. Pediatr. Dermatol. 36, 303\u2013310 (2019).","journal-title":"Pediatr. Dermatol."},{"key":"735_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jaad.2019.03.037","volume":"81","author":"L Eckert","year":"2019","unstructured":"Eckert, L., Gupta, S., Gadkari, A., Mahajan, P. & Gelfand, J. M. Burden of illness in adults with atopic dermatitis: analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. J. Am. Acad. Dermatol. 81, 187\u2013195 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/bjd.18636","volume":"182","author":"N Ismail","year":"2020","unstructured":"Ismail, N. & Bray, N. Atopic dermatitis: economic burden and strategies for high-quality care. Br. J. Dermatol. 182, 1087\u20131088 (2020).","journal-title":"Br. J. Dermatol."},{"key":"735_CR21","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1007\/s12325-022-02120-6","volume":"39","author":"C Weil","year":"2022","unstructured":"Weil, C. et al. Epidemiology and economic burden of atopic dermatitis: real-world retrospective data from a large nationwide Israeli healthcare provider database. Adv. Ther. 39, 2502\u20132514 (2022).","journal-title":"Adv. Ther."},{"key":"735_CR22","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jaad.2015.02.1099","volume":"72","author":"J Vanderpuye-Orgle","year":"2015","unstructured":"Vanderpuye-Orgle, J. et al. Evaluating the economic burden of psoriasis in the United States. J. Am. Acad. Dermatol. 72, 961\u2013967.e5 (2015).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s13555-022-00832-9","volume":"13","author":"JJ Wu","year":"2023","unstructured":"Wu, J. J. et al. Economic burden of comorbidities in patients with psoriasis in the USA. Dermatol. Ther. 13, 207\u2013219 (2023).","journal-title":"Dermatol. Ther."},{"key":"735_CR24","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jamadermatol.2021.3668","volume":"157","author":"L Maintz","year":"2021","unstructured":"Maintz, L. et al. Machine learning-based deep phenotyping of atopic dermatitis: severity-associated factors in adolescent and adult patients. JAMA Dermatol. 157, 1414\u20131424 (2021).","journal-title":"JAMA Dermatol."},{"key":"735_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","volume":"124","author":"JI Silverberg","year":"2019","unstructured":"Silverberg, J. I. Comorbidities and the impact of atopic dermatitis. Ann. Allergy Asthma Immunol. 124, 144\u2013151 (2019).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"735_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.2340\/00015555-3175","volume":"99","author":"WL Kok","year":"2019","unstructured":"Kok, W. L., Yew, Y. W. & Thng, T. G. Comorbidities associated with severity of atopic dermatitis in young adult males: a national cohort study. Acta Derm. Venereol. 99, 652\u2013656 (2019).","journal-title":"Acta Derm. Venereol."},{"key":"735_CR27","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jaad.2017.01.030","volume":"76","author":"JP Thyssen","year":"2017","unstructured":"Thyssen, J. P., Skov, L., Hamann, C. R., Gislason, G. H. & Egeberg, A. Assessment of major comorbidities in adults with atopic dermatitis using the Charlson comorbidity index. J. Am. Acad. Dermatol. 76, 1088\u20131092.e1 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR28","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jaci.2019.01.003","volume":"143","author":"WF Davidson","year":"2019","unstructured":"Davidson, W. F. et al. Report from the National Institute of Allergy and Infectious Diseases workshop on \u2018Atopic dermatitis and the atopic march: mechanisms and interventions\u2019. J. Allergy Clin. Immunol. 143, 894\u2013913 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR29","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.jaci.2022.03.008","volume":"149","author":"J Takeshita","year":"2022","unstructured":"Takeshita, J. et al. Atopic dermatitis and the atopic march: considering racial and ethnic diversity in atopic disease progression. J. Allergy Clin. Immunol. 149, 1590\u20131591 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/imr.12546","volume":"278","author":"H Han","year":"2017","unstructured":"Han, H., Roan, F. & Ziegler, S. F. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol. Rev. 278, 116\u2013130 (2017).","journal-title":"Immunol. Rev."},{"key":"735_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/all.13228","volume":"73","author":"SJ Khan","year":"2018","unstructured":"Khan, S. J., Dharmage, S. C., Matheson, M. C. & Gurrin, L. C. Is the atopic march related to confounding by genetics and early-life environment? A systematic review of sibship and twin data. Allergy 73, 17\u201328 (2018).","journal-title":"Allergy"},{"key":"735_CR32","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/all.13085","volume":"72","author":"A Egeberg","year":"2017","unstructured":"Egeberg, A., Andersen, Y. M., Gislason, G. H., Skov, L. & Thyssen, J. P. Prevalence of comorbidity and associated risk factors in adults with atopic dermatitis. Allergy 72, 783\u2013791 (2017).","journal-title":"Allergy"},{"key":"735_CR33","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/all.13360","volume":"73","author":"YMF Andersen","year":"2017","unstructured":"Andersen, Y. M. F. et al. Poor agreement in questionnaire-based diagnostic criteria for adult atopic dermatitis is a challenge when examining cardiovascular comorbidity. Allergy 73, 923\u2013931 (2017).","journal-title":"Allergy"},{"key":"735_CR34","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1111\/all.14859","volume":"76","author":"AP Villani","year":"2021","unstructured":"Villani, A. P. et al. Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. Allergy 76, 3107\u20133121 (2021).","journal-title":"Allergy"},{"key":"735_CR35","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2340\/00015555-3235","volume":"99","author":"LU Ivert","year":"2019","unstructured":"Ivert, L. U. et al. Association between atopic dermatitis and cardiovascular disease: a nationwide register-based case\u2013control study from Sweden. Acta Derm. Venereol. 99, 865\u2013870 (2019).","journal-title":"Acta Derm. Venereol."},{"key":"735_CR36","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","volume":"151","author":"GC Mohan","year":"2015","unstructured":"Mohan, G. C. & Silverberg, J. I. Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 151, 522\u2013528 (2015).","journal-title":"JAMA Dermatol."},{"key":"735_CR37","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/all.13128","volume":"72","author":"AM Drucker","year":"2017","unstructured":"Drucker, A. M. et al. Incident alopecia areata and vitiligo in adult women with atopic dermatitis: nurses\u2019 health study 2. Allergy 72, 831\u2013834 (2017).","journal-title":"Allergy"},{"key":"735_CR38","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.clindermatol.2017.03.008","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg, J. I. Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders. Clin. Dermatol. 35, 360\u2013366 (2017).","journal-title":"Clin. Dermatol."},{"key":"735_CR39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/all.13231","volume":"73","author":"JP Thyssen","year":"2018","unstructured":"Thyssen, J. P. et al. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy 73, 214\u2013220 (2018).","journal-title":"Allergy"},{"key":"735_CR40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/exd.14071","volume":"29","author":"MT Ayasse","year":"2020","unstructured":"Ayasse, M. T., Buddenkotte, J., Alam, M. & Steinhoff, M. Role of neuroimmune circuits and pruritus in psoriasis. Exp. Dermatol. 29, 414\u2013426 (2020).","journal-title":"Exp. Dermatol."},{"key":"735_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s42358-019-0081-9","volume":"59","author":"JA Mendonca","year":"2019","unstructured":"Mendonca, J. A., Aydin, S. Z. & D\u2019Agostino, M. A. The use of ultrasonography in the diagnosis of nail disease among patients with psoriasis and psoriatic arthritis: a systematic review. Adv. Rheumatol. 59, 41 (2019).","journal-title":"Adv. Rheumatol."},{"key":"735_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fphar.2020.00117","volume":"11","author":"P Gisondi","year":"2020","unstructured":"Gisondi, P., Bellinato, F., Girolomoni, G. & Albanesi, C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front. Pharmacol. 11, 117 (2020).","journal-title":"Front. Pharmacol."},{"key":"735_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jaad.2016.11.037","volume":"76","author":"MD Saleem","year":"2017","unstructured":"Saleem, M. D., Kesty, C. & Feldman, S. R. Relative versus absolute risk of comorbidities in patients with psoriasis. J. Am. Acad. Dermatol. 76, 531\u2013537 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR44","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","volume":"9","author":"WH Boehncke","year":"2018","unstructured":"Boehncke, W. H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front. Immunol. 9, 579 (2018).","journal-title":"Front. Immunol."},{"key":"735_CR45","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong, A. W. & Read, C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. J. Am. Med. Assoc. 323, 1945\u20131960 (2020).","journal-title":"J. Am. Med. Assoc."},{"key":"735_CR46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","volume":"20","author":"WH Boehncke","year":"2011","unstructured":"Boehncke, W. H., Boehncke, S., Tobin, A. M. & Kirby, B. The \u2018psoriatic march\u2019: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp. Dermatol. 20, 303\u2013307 (2011).","journal-title":"Exp. Dermatol."},{"key":"735_CR47","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/j.1468-3083.2012.04599.x","volume":"27","author":"YS Su","year":"2013","unstructured":"Su, Y. S. et al. Psoriasis as initiator or amplifier of the systemic inflammatory march: impact on development of severe vascular events and implications for treatment strategy. J. Eur. Acad. Dermatol. Venereol. 27, 876\u2013883 (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"735_CR48","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/exd.13699","volume":"27","author":"A Boehner","year":"2018","unstructured":"Boehner, A., Navarini, A. A. & Eyerich, K. Generalized pustular psoriasis \u2014 a model disease for specific targeted immunotherapy, systematic review. Exp. Dermatol. 27, 1067\u20131077 (2018).","journal-title":"Exp. Dermatol."},{"key":"735_CR49","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","volume":"31","author":"AA Navarini","year":"2017","unstructured":"Navarini, A. A. et al. European consensus statement on phenotypes of pustular psoriasis. J. Eur. Acad. Dermatol. Venereol. 31, 1792\u20131799 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"735_CR50","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1111\/jdv.14136","volume":"31","author":"M Misiak-Galazka","year":"2017","unstructured":"Misiak-Galazka, M., Wolska, H. & Rudnicka, L. Is palmoplantar pustulosis simply a variant of psoriasis or a distinct entity? J. Eur. Acad. Dermatol. Venereol. 31, e342\u2013e343 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"735_CR51","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/09546631003636817","volume":"22","author":"AC de Waal","year":"2011","unstructured":"de Waal, A. C. & van de Kerkhof, P. C. Pustulosis palmoplantaris is a disease distinct from psoriasis. J. Dermatol. Treat. 22, 102\u2013105 (2011).","journal-title":"J. Dermatol. Treat."},{"key":"735_CR52","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jdv.18851","volume":"37","author":"L Puig","year":"2023","unstructured":"Puig, L. et al. Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals, and disease management. J. Eur. Acad. Dermatol. Venereol. 37, 737\u2013752 (2023).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"735_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40257-021-00664-x","volume":"23","author":"M Zheng","year":"2022","unstructured":"Zheng, M., Jullien, D. & Eyerich, K. The prevalence and disease characteristics of generalized pustular psoriasis. Am. J. Clin. Dermatol. 23, 5\u201312 (2022).","journal-title":"Am. J. Clin. Dermatol."},{"key":"735_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.12788\/cutis.0579","volume":"110","author":"KA Reynolds","year":"2022","unstructured":"Reynolds, K. A. et al. Generalized pustular psoriasis: a review of the pathophysiology, clinical manifestations, diagnosis, and treatment. Cutis 110, 19\u201325 (2022).","journal-title":"Cutis"},{"key":"735_CR55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/09546634.2017.1336829","volume":"28","author":"PC van de Kerkhof","year":"2017","unstructured":"van de Kerkhof, P. C. Biologics for psoriasis: maintenance treatment and true disease modification. J. Dermatol. Treat. 28, 281 (2017).","journal-title":"J. Dermatol. Treat."},{"key":"735_CR56","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/j.1398-9995.2012.02845.x","volume":"67","author":"T Bieber","year":"2012","unstructured":"Bieber, T., Cork, M. & Reitamo, S. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy 67, 969\u2013975 (2012).","journal-title":"Allergy"},{"key":"735_CR57","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/ni.2680","volume":"14","author":"WR Heath","year":"2013","unstructured":"Heath, W. R. & Carbone, F. R. The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat. Immunol. 14, 978\u2013985 (2013).","journal-title":"Nat. Immunol."},{"key":"735_CR58","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nri3646","volume":"14","author":"M Pasparakis","year":"2014","unstructured":"Pasparakis, M., Haase, I. & Nestle, F. O. Mechanisms regulating skin immunity and inflammation. Nat. Rev. Immunol. 14, 289\u2013301 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"735_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K. & Irvine, A. D. Atopic dermatitis. Nat. Rev. Dis. Prim. 4, 1 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"735_CR60","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1684\/ejd.2021.4015","volume":"31","author":"A Nosbaum","year":"2021","unstructured":"Nosbaum, A. et al. Psoriasis is a disease of the entire skin: non-lesional skin displays a prepsoriasis phenotype. Eur. J. Dermatol. 31, 143\u2013154 (2021).","journal-title":"Eur. J. Dermatol."},{"key":"735_CR61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-immunol-093019-123619","volume":"39","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. & Cao, X. Epigenetic remodeling in innate immunity and inflammation. Annu. Rev. Immunol. 39, 279\u2013311 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"735_CR62","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41590-022-01229-8","volume":"23","author":"JT Crowl","year":"2022","unstructured":"Crowl, J. T. et al. Tissue-resident memory CD8(+) T cells possess unique transcriptional, epigenetic and functional adaptations to different tissue environments. Nat. Immunol. 23, 1121\u20131131 (2022).","journal-title":"Nat. Immunol."},{"key":"735_CR63","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41577-022-00767-4","volume":"22","author":"TMH Luong","year":"2022","unstructured":"Luong, T. M. H. & Buggert, M. Tissue-specific epigenomics of resident memory CD8(+) T cells. Nat. Rev. Immunol. 22, 533 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"735_CR64","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41586-022-04919-3","volume":"607","author":"S Naik","year":"2022","unstructured":"Naik, S. & Fuchs, E. Inflammatory memory and tissue adaptation in sickness and in health. Nature 607, 249\u2013255 (2022).","journal-title":"Nature"},{"key":"735_CR65","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","volume":"137","author":"PM Brunner","year":"2017","unstructured":"Brunner, P. M. et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J. Invest. Dermatol. 137, 18\u201325 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR66","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jaci.2017.12.991","volume":"141","author":"JL Thijs","year":"2018","unstructured":"Thijs, J. L. et al. Serum biomarker profiles suggest that atopic dermatitis is a systemic disease. J. Allergy Clin. Immunol. 141, 1523\u20131526 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR67","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.det.2014.09.004","volume":"33","author":"C Ryan","year":"2015","unstructured":"Ryan, C. & Kirby, B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol. Clin. 33, 41\u201355 (2015).","journal-title":"Dermatol. Clin."},{"key":"735_CR68","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/jdv.15339","volume":"33","author":"E Christophers","year":"2019","unstructured":"Christophers, E. & van de Kerkhof, P. C. M. Severity, heterogeneity and systemic inflammation in psoriasis. J. Eur. Acad. Dermatol. Venereol. 33, 643\u2013647 (2019).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"735_CR69","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman, N. J. Management of psoriasis as a systemic disease: what is the evidence? Br. J. Dermatol. 182, 840\u2013848 (2020).","journal-title":"Br. J. Dermatol."},{"key":"735_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000067","volume":"7","author":"S Demehri","year":"2009","unstructured":"Demehri, S., Morimoto, M., Holtzman, M. J. & Kopan, R. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. PLoS Biol. 7, e1000067 (2009).","journal-title":"PLoS Biol."},{"key":"735_CR71","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nature10329","volume":"477","author":"MC Siracusa","year":"2011","unstructured":"Siracusa, M. C. et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature 477, 229\u2013233 (2011).","journal-title":"Nature"},{"key":"735_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/srep00023","volume":"1","author":"Z Zhu","year":"2011","unstructured":"Zhu, Z., Oh, M. H., Yu, J., Liu, Y. J. & Zheng, T. The role of TSLP in IL-13-induced atopic march. Sci. Rep. 1, 23 (2011).","journal-title":"Sci. Rep."},{"key":"735_CR73","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jaci.2015.06.009","volume":"136","author":"K Yamanaka","year":"2015","unstructured":"Yamanaka, K. & Mizutani, H. \u2018Inflammatory skin march\u2019: IL-1-mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events. J. Allergy Clin. Immunol. 136, 823\u2013824 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR74","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jaci.2015.06.045","volume":"137","author":"SP Saunders","year":"2016","unstructured":"Saunders, S. P. et al. Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. J. Allergy Clin. Immunol. 137, 482\u2013491 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR75","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/mi.2017.10","volume":"10","author":"L Yi","year":"2017","unstructured":"Yi, L. et al. Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitis. Mucosal Immunol. 10, 1491\u20131503 (2017).","journal-title":"Mucosal Immunol."},{"key":"735_CR76","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00011-017-1065-z","volume":"66","author":"M Furue","year":"2017","unstructured":"Furue, M. & Kadono, T. \u2018Inflammatory skin march\u2019 in atopic dermatitis and psoriasis. Inflamm. Res. 66, 833\u2013842 (2017).","journal-title":"Inflamm. Res."},{"key":"735_CR77","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jaci.2020.08.041","volume":"147","author":"H He","year":"2021","unstructured":"He, H. et al. Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities. J. Allergy Clin. Immunol. 147, 1369\u20131380 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR78","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/jpm12060893","volume":"12","author":"L Maintz","year":"2022","unstructured":"Maintz, L., Bieber, T., Simpson, H. D. & Demessant-Flavigny, A. L. From skin barrier dysfunction to systemic impact of atopic dermatitis: implications for a precision approach in dermocosmetics and medicine. J. Pers. Med. 12, 893 (2022).","journal-title":"J. Pers. Med."},{"key":"735_CR79","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","volume":"55","author":"AL Neimann","year":"2006","unstructured":"Neimann, A. L. et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 55, 829\u2013835 (2006).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR80","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand, J. M. et al. Risk of myocardial infarction in patients with psoriasis. J. Am. Med. Assoc. 296, 1735\u20131741 (2006).","journal-title":"J. Am. Med. Assoc."},{"key":"735_CR81","doi-asserted-by":"publisher","first-page":"775.e1","DOI":"10.1016\/j.amjmed.2011.03.028","volume":"124","author":"NN Mehta","year":"2011","unstructured":"Mehta, N. N. et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am. J. Med. 124, 775.e1\u20136 (2011).","journal-title":"Am. J. Med."},{"key":"735_CR82","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","volume":"77","author":"A Egeberg","year":"2017","unstructured":"Egeberg, A. et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J. Am. Acad. Dermatol. 77, 650\u2013656.e3 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR83","first-page":"214","volume":"112","author":"WP Buffum","year":"1966","unstructured":"Buffum, W. P. & Settipane, G. A. Prognosis of asthma in childhood. Am. J. Dis. Child. 112, 214\u2013217 (1966).","journal-title":"Am. J. Dis. Child."},{"key":"735_CR84","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.otc.2011.03.006","volume":"44","author":"BR Gordon","year":"2011","unstructured":"Gordon, B. R. The allergic march: can we prevent allergies and asthma? Otolaryngol. Clin. North Am. 44, 765\u2013777 (2011).","journal-title":"Otolaryngol. Clin. North Am."},{"key":"735_CR85","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaci.2007.05.042","volume":"120","author":"AE van der Hulst","year":"2007","unstructured":"van der Hulst, A. E., Klip, H. & Brand, P. L. Risk of developing asthma in young children with atopic eczema: a systematic review. J. Allergy Clin. Immunol. 120, 565\u2013569 (2007).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR86","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1034\/j.1398-9995.2000.00391.x","volume":"55","author":"D Gustafsson","year":"2000","unstructured":"Gustafsson, D., Sjoberg, O. & Foucard, T. Development of allergies and asthma in infants and young children with atopic dermatitis \u2014 a prospective follow-up to 7 years of age. Allergy 55, 240\u2013245 (2000).","journal-title":"Allergy"},{"key":"735_CR87","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","volume":"127","author":"M Suarez-Farinas","year":"2011","unstructured":"Suarez-Farinas, M. et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J. Allergy Clin. Immunol. 127, 954\u2013964 (2011).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR88","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1111\/all.13223","volume":"72","author":"PM Brunner","year":"2017","unstructured":"Brunner, P. M. et al. Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues. Allergy 72, 2017\u20132025 (2017).","journal-title":"Allergy"},{"key":"735_CR89","doi-asserted-by":"publisher","first-page":"eaav2685","DOI":"10.1126\/scitranslmed.aav2685","volume":"11","author":"DYM Leung","year":"2019","unstructured":"Leung, D. Y. M. et al. The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype. Sci. Transl. Med. 11, eaav2685 (2019).","journal-title":"Sci. Transl. Med."},{"key":"735_CR90","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/all.14490","volume":"76","author":"AB Pavel","year":"2021","unstructured":"Pavel, A. B. et al. Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. Allergy 76, 314\u2013325 (2021).","journal-title":"Allergy"},{"key":"735_CR91","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1111\/all.15423","volume":"77","author":"Y Renert-Yuval","year":"2022","unstructured":"Renert-Yuval, Y. et al. Tape strips capture atopic dermatitis-related changes in nonlesional skin throughout maturation. Allergy 77, 3445\u20133447 (2022).","journal-title":"Allergy"},{"key":"735_CR92","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","volume":"147","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval, Y. et al. Biomarkers in atopic dermatitis \u2014 a review on behalf of the International Eczema Council. J. Allergy Clin. Immunol. 147, 1174\u20131190.e1 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR93","doi-asserted-by":"publisher","DOI":"10.1111\/all.15647","author":"L Maintz","year":"2023","unstructured":"Maintz, L. et al. IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype\u2013phenotype associations in atopic dermatitis. Allergy https:\/\/doi.org\/10.1111\/all.15647 (2023).","journal-title":"Allergy"},{"key":"735_CR94","first-page":"11","volume":"12","author":"JL Cummings","year":"2007","unstructured":"Cummings, J. L. Measuring disease modification in Alzheimer\u2019s disease. CNS Spectr. 12, 11\u201314 (2007).","journal-title":"CNS Spectr."},{"key":"735_CR95","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1474-4422(06)70677-9","volume":"6","author":"B Vellas","year":"2007","unstructured":"Vellas, B., Andrieu, S., Sampaio, C. & Wilcock, G., European Task Force Group. Disease-modifying trials in Alzheimer\u2019s disease: a European task force consensus. Lancet Neurol. 6, 56\u201362 (2007).","journal-title":"Lancet Neurol."},{"key":"735_CR96","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd2896","volume":"9","author":"M Citron","year":"2010","unstructured":"Citron, M. Alzheimer\u2019s disease: strategies for disease modification. Nat. Rev. Drug Discov. 9, 387\u2013398 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"735_CR97","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40035-017-0096-2","volume":"6","author":"J Cummings","year":"2017","unstructured":"Cummings, J. Disease modification and neuroprotection in neurodegenerative disorders. Transl. Neurodegener. 6, 25 (2017).","journal-title":"Transl. Neurodegener."},{"key":"735_CR98","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s43441-019-00068-4","volume":"54","author":"H Liu-Seifert","year":"2020","unstructured":"Liu-Seifert, H. et al. Disease modification in Alzheimer\u2019s disease: current thinking. Ther. Innov. Regul. Sci. 54, 396\u2013403 (2020).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"735_CR99","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s00415-020-10162-5","volume":"268","author":"M Smedinga","year":"2021","unstructured":"Smedinga, M., Darweesh, S. K. L., Bloem, B. R., Post, B. & Richard, E. Towards early disease modification of Parkinson\u2019s disease: a review of lessons learned in the Alzheimer field. J. Neurol. 268, 724\u2013733 (2021).","journal-title":"J. Neurol."},{"key":"735_CR100","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","volume":"20","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R. & Foltynie, T. Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol. 20, 559\u2013572 (2021).","journal-title":"Lancet Neurol."},{"key":"735_CR101","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejpn.2019.12.005","volume":"24","author":"JH Cross","year":"2020","unstructured":"Cross, J. H. & Lagae, L. The concept of disease modification. Eur. J. Paediatr. Neurol. 24, 43\u201346 (2020).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"735_CR102","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/7854_2020_216","volume":"55","author":"E Russo","year":"2022","unstructured":"Russo, E. & Citraro, R. Disease modification in epilepsy: behavioural accompaniments. Curr. Top. Behav. Neurosci. 55, 145\u2013167 (2022).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"735_CR103","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1684\/j.1950-6945.2003.tb00025.x","volume":"5","author":"H Klitgaard","year":"2003","unstructured":"Klitgaard, H. & Pitkanen, A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord. 5, S9\u2013S16 (2003).","journal-title":"Epileptic Disord."},{"key":"735_CR104","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/epi4.12526","volume":"6","author":"JA French","year":"2021","unstructured":"French, J. A. et al. Antiepileptogenesis and disease modification: clinical and regulatory issues. Epilepsia Open 6, 483\u2013492 (2021).","journal-title":"Epilepsia Open"},{"key":"735_CR105","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3899\/jrheum.200310","volume":"48","author":"JG Hanly","year":"2021","unstructured":"Hanly, J. G. & Lethbridge, L. Use of disease-modifying antirheumatic drugs, biologics, and corticosteroids in older patients with rheumatoid arthritis over 20 years. J. Rheumatol. 48, 977\u2013984 (2021).","journal-title":"J. Rheumatol."},{"key":"735_CR106","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/ncprheum0193","volume":"2","author":"SB Abramson","year":"2006","unstructured":"Abramson, S. B., Attur, M. & Yazici, Y. Prospects for disease modification in osteoarthritis. Nat. Clin. Pract. Rheumatol. 2, 304\u2013312 (2006).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"735_CR107","first-page":"135","volume":"37","author":"WM Oo","year":"2019","unstructured":"Oo, W. M. & Hunter, D. J. Disease modification in osteoarthritis: are we there yet? Clin. Exp. Rheumatol. 37, 135\u2013140 (2019).","journal-title":"Clin. Exp. Rheumatol."},{"key":"735_CR108","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","volume":"393","author":"DJ Hunter","year":"2019","unstructured":"Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. Lancet 393, 1745\u20131759 (2019).","journal-title":"Lancet"},{"key":"735_CR109","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/art.41246","volume":"72","author":"V Nagaraja","year":"2020","unstructured":"Nagaraja, V. et al. Current and future outlook on disease modification and defining low disease activity in systemic sclerosis. Arthritis Rheumatol. 72, 1049\u20131058 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"735_CR110","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/09546634.2020.1729335","volume":"33","author":"S Segaert","year":"2022","unstructured":"Segaert, S. et al. Long-term topical management of psoriasis: the road ahead. J. Dermatol. Treat. 33, 111\u2013120 (2022).","journal-title":"J. Dermatol. Treat."},{"key":"735_CR111","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/09546634.2020.1743811","volume":"33","author":"N Yasmeen","year":"2022","unstructured":"Yasmeen, N. et al. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J. Dermatol. Treat. 33, 204\u2013218 (2022).","journal-title":"J. Dermatol. Treat."},{"key":"735_CR112","doi-asserted-by":"publisher","first-page":"257","DOI":"10.55563\/clinexprheumatol\/8thj0l","volume":"38","author":"D Solmaz","year":"2020","unstructured":"Solmaz, D. et al. Evidence that systemic therapies for psoriasis may reduce psoriatic arthritis occurrence. Clin. Exp. Rheumatol. 38, 257\u2013261 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"735_CR113","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1358\/dot.2021.57.5.3266244","volume":"57","author":"S Magina","year":"2021","unstructured":"Magina, S. & Filipe, P. Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification. Drugs Today 57, 347\u2013357 (2021).","journal-title":"Drugs Today"},{"key":"735_CR114","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi, K., Balato, A., Enerback, C. & Sabat, R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 397, 754\u2013766 (2021).","journal-title":"Lancet"},{"key":"735_CR115","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1111\/jdv.14979","volume":"32","author":"L Iversen","year":"2018","unstructured":"Iversen, L. et al. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification \u2014 rationale and design of the randomized, multicenter STEPIn study. J. Eur. Acad. Dermatol. Venereol. 32, 1930\u20131939 (2018).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"735_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-020-00327-w","volume":"10","author":"V Mahler","year":"2020","unstructured":"Mahler, V. et al. Allergen immunotherapy (AIT) in children: a vulnerable population with its own rights and legislation \u2014 summary of EMA-initiated multi-stakeholder meeting on Allergen Immunotherapy (AIT) for children, held at Paul-Ehrlich-Institut, Langen, Germany, 16.1.2019. Clin. Transl. Allergy 10, 28 (2020).","journal-title":"Clin. Transl. Allergy"},{"key":"735_CR117","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber, T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy 75, 54\u201362 (2020).","journal-title":"Allergy"},{"key":"735_CR118","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi, L. C. et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J. Invest. Dermatol. 139, 1480\u20131489 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR119","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jaci.2019.09.031","volume":"145","author":"T Czarnowicki","year":"2020","unstructured":"Czarnowicki, T. et al. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J. Allergy Clin. Immunol. 145, 215\u2013228 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR120","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","volume":"139","author":"T Bieber","year":"2017","unstructured":"Bieber, T. et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J. Allergy Clin. Immunol. 139, S58\u2013S64 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR121","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","volume":"80","author":"YW Yew","year":"2019","unstructured":"Yew, Y. W., Thyssen, J. P. & Silverberg, J. I. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J. Am. Acad. Dermatol. 80, 390\u2013401 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR122","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1067\/S0190-9622(03)00896-X","volume":"49","author":"A Wollenberg","year":"2003","unstructured":"Wollenberg, A., Zoch, C., Wetzel, S., Plewig, G. & Przybilla, B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J. Am. Acad. Dermatol. 49, 198\u2013205 (2003).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR123","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1398-9995.2010.02538.x","volume":"66","author":"T Hinz","year":"2011","unstructured":"Hinz, T. et al. Atopic dermo-respiratory syndrome is a correlate of eczema herpeticum. Allergy 66, 925\u2013933 (2011).","journal-title":"Allergy"},{"key":"735_CR124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001748","volume":"11","author":"DC Belgrave","year":"2014","unstructured":"Belgrave, D. C. et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 11, e1001748 (2014).","journal-title":"PLoS Med."},{"key":"735_CR125","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/all.12844","volume":"71","author":"E Lee","year":"2016","unstructured":"Lee, E. et al. Atopic dermatitis phenotype with early onset and high serum IL-13 is linked to the new development of bronchial hyperresponsiveness in school children. Allergy 71, 692\u2013700 (2016).","journal-title":"Allergy"},{"key":"735_CR126","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jaad.2017.06.013","volume":"77","author":"J Wan","year":"2017","unstructured":"Wan, J. et al. Variations in risk of asthma and seasonal allergies between early- and late-onset pediatric atopic dermatitis: a cohort study. J. Am. Acad. Dermatol. 77, 634\u2013640 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR127","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamapediatrics.2017.0556","volume":"171","author":"C Roduit","year":"2017","unstructured":"Roduit, C. et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr. 171, 655\u2013662 (2017).","journal-title":"JAMA Pediatr."},{"key":"735_CR128","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jaci.2017.09.044","volume":"141","author":"L Paternoster","year":"2018","unstructured":"Paternoster, L. et al. Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts. J. Allergy Clin. Immunol. 141, 964\u2013971 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR129","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jid.2019.08.432","volume":"140","author":"R Berna","year":"2020","unstructured":"Berna, R., Mitra, N., Hoffstad, O., Wan, J. & Margolis, D. J. Identifying phenotypes of atopic dermatitis in a longitudinal United States cohort using unbiased statistical clustering. J. Invest. Dermatol. 140, 477\u2013479 (2020).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR130","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/all.12112","volume":"68","author":"D Garmhausen","year":"2013","unstructured":"Garmhausen, D. et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy 68, 498\u2013506 (2013).","journal-title":"Allergy"},{"key":"735_CR131","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1056\/NEJMra1011040","volume":"365","author":"AD Irvine","year":"2011","unstructured":"Irvine, A. D., McLean, W. H. & Leung, D. Y. Filaggrin mutations associated with skin and allergic diseases. N. Engl. J. Med. 365, 1315\u20131327 (2011).","journal-title":"N. Engl. J. Med."},{"key":"735_CR132","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bjd.20946","volume":"186","author":"DJ Margolis","year":"2022","unstructured":"Margolis, D. J. Atopic dermatitis: filaggrin and skin barrier dysfunction. Br. J. Dermatol. 186, 396 (2022).","journal-title":"Br. J. Dermatol."},{"key":"735_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33906-5","volume":"13","author":"L Moitinho-Silva","year":"2022","unstructured":"Moitinho-Silva, L. et al. Host genetic factors related to innate immunity, environmental sensing and cellular functions are associated with human skin microbiota. Nat. Commun. 13, 6204 (2022).","journal-title":"Nat. Commun."},{"key":"735_CR134","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.annder.2021.02.003","volume":"148","author":"J Beaziz","year":"2021","unstructured":"Beaziz, J., Bouaziz, J. D., Jachiet, M., Fite, C. & Lons-Danic, D. Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature. Ann. Dermatol. Venereol. 148, 198\u2013201 (2021).","journal-title":"Ann. Dermatol. Venereol."},{"key":"735_CR135","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jaad.2021.05.013","volume":"86","author":"CM Brumfiel","year":"2022","unstructured":"Brumfiel, C. M., Patel, M. H. & Zirwas, M. J. Development of psoriasis during treatment with dupilumab: a systematic review. J. Am. Acad. Dermatol. 86, 708\u2013709 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR136","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","volume":"142","author":"C Bridgewood","year":"2022","unstructured":"Bridgewood, C. et al. T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17-type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases. J. Invest. Dermatol. 142, 2660\u20132667 (2022).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR137","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","volume":"151","author":"GP Geba","year":"2023","unstructured":"Geba, G. P. et al. Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J. Allergy Clin. Immunol. 151, 756\u2013766 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR138","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jaci.2022.12.824","volume":"151","author":"T Bieber","year":"2023","unstructured":"Bieber, T. In search of the Holy Grail in atopic dermatitis: will dupilumab become the first disease-modifying atopic dermatitis drug? J. Allergy Clin. Immunol. 151, 694\u2013696 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR139","first-page":"202","volume":"5","author":"SK Bantz","year":"2014","unstructured":"Bantz, S. K., Zhu, Z. & Zheng, T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J. Clin. Cell Immunol. 5, 202 (2014).","journal-title":"J. Clin. Cell Immunol."},{"key":"735_CR140","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.smim.2017.07.005","volume":"30","author":"M Westman","year":"2017","unstructured":"Westman, M., Asarnoj, A., Hamsten, C., Wickman, M. & van Hage, M. Windows of opportunity for tolerance induction for allergy by studying the evolution of allergic sensitization in birth cohorts. Semin. Immunol. 30, 61\u201366 (2017).","journal-title":"Semin. Immunol."},{"key":"735_CR141","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jaci.2017.11.019","volume":"141","author":"H Renz","year":"2018","unstructured":"Renz, H. et al. The neonatal window of opportunity-early priming for life. J. Allergy Clin. Immunol. 141, 1212\u20131214 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR142","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","volume":"136","author":"S Noda","year":"2015","unstructured":"Noda, S. et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J. Allergy Clin. Immunol. 136, 1254\u20131264 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR143","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jaci.2018.02.047","volume":"142","author":"HC Wen","year":"2018","unstructured":"Wen, H. C. et al. Serum from Asian patients with atopic dermatitis is characterized by T(H)2\/T(H)22 activation, which is highly correlated with nonlesional skin measures. J. Allergy Clin. Immunol. 142, 324\u2013328.e11 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR144","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaci.2018.06.016","volume":"142","author":"TC Chan","year":"2018","unstructured":"Chan, T. C. et al. Atopic dermatitis in Chinese patients shows T(H)2\/T(H)17 skewing with psoriasiform features. J. Allergy Clin. Immunol. 142, 1013\u20131017 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR145","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","volume":"122","author":"PM Brunner","year":"2019","unstructured":"Brunner, P. M. & Guttman-Yassky, E. Racial differences in atopic dermatitis. Ann. Allergy Asthma Immunol. 122, 449\u2013455 (2019).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"735_CR146","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/jdv.16871","volume":"35","author":"CCV Lang","year":"2021","unstructured":"Lang, C. C. V. et al. Evidence for different immune signatures and sensitization patterns in sub-Saharan African vs. Central European atopic dermatitis patients. J. Eur. Acad. Dermatol. Venereol. 35, e140\u2013e142 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"735_CR147","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/j.jaci.2021.09.036","volume":"149","author":"JM Biagini","year":"2022","unstructured":"Biagini, J. M. et al. Longitudinal atopic dermatitis endotypes: an atopic march paradigm that includes Black children. J. Allergy Clin. Immunol. 149, 1702\u20131710.e4 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR148","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jaci.2004.01.778","volume":"113","author":"S Illi","year":"2004","unstructured":"Illi, S. et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J. Allergy Clin. Immunol. 113, 925\u2013931 (2004).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR149","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jaci.2010.06.020","volume":"126","author":"AS Peters","year":"2010","unstructured":"Peters, A. S. et al. Prediction of the incidence, recurrence, and persistence of atopic dermatitis in adolescence: a prospective cohort study. J. Allergy Clin. Immunol. 126, 590\u2013595 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR150","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1398-9995.2012.02786.x","volume":"67","author":"N Ballardini","year":"2012","unstructured":"Ballardini, N. et al. Development and comorbidity of eczema, asthma and rhinitis to age 12: data from the BAMSE birth cohort. Allergy 67, 537\u2013544 (2012).","journal-title":"Allergy"},{"key":"735_CR151","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaci.2013.09.015","volume":"133","author":"DJ Margolis","year":"2014","unstructured":"Margolis, D. J. et al. Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects. J. Allergy Clin. Immunol. 133, 784\u2013789 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR152","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00403-021-02319-7","volume":"314","author":"R Berna","year":"2022","unstructured":"Berna, R. et al. Uncommon variants in FLG2 and TCHHL1 are associated with remission of atopic dermatitis in a large longitudinal US cohort. Arch. Dermatol. Res. 314, 953\u2013959 (2022).","journal-title":"Arch. Dermatol. Res."},{"key":"735_CR153","doi-asserted-by":"publisher","first-page":"6484","DOI":"10.3390\/ijms21186484","volume":"21","author":"B Nedoszytko","year":"2020","unstructured":"Nedoszytko, B. et al. Genetic and epigenetic aspects of atopic dermatitis. Int. J. Mol. Sci. 21, 6484 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"735_CR154","doi-asserted-by":"publisher","first-page":"630892","DOI":"10.3389\/fimmu.2021.630892","volume":"12","author":"K Rindler","year":"2021","unstructured":"Rindler, K. et al. Spontaneously resolved atopic dermatitis shows melanocyte and immune cell activation distinct from healthy control skin. Front. Immunol. 12, 630892 (2021).","journal-title":"Front. Immunol."},{"key":"735_CR155","doi-asserted-by":"publisher","first-page":"eabe2749","DOI":"10.1126\/sciimmunol.abe2749","volume":"6","author":"C Bangert","year":"2021","unstructured":"Bangert, C. et al. Persistence of mature dendritic cells, T(H)2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Ralpha blockade. Sci. Immunol. 6, eabe2749 (2021).","journal-title":"Sci. Immunol."},{"key":"735_CR156","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.20082242","volume":"206","author":"A Briot","year":"2009","unstructured":"Briot, A. et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J. Exp. Med. 206, 1135\u20131147 (2009).","journal-title":"J. Exp. Med."},{"key":"735_CR157","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jaci.2016.07.029","volume":"139","author":"EA Kennedy","year":"2017","unstructured":"Kennedy, E. A. et al. Skin microbiome before development of atopic dermatitis: early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year. J. Allergy Clin. Immunol. 139, 166\u2013172 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR158","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.tim.2017.11.008","volume":"26","author":"JA Geoghegan","year":"2018","unstructured":"Geoghegan, J. A., Irvine, A. D. & Foster, T. J. Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship. Trends Microbiol. 26, 484\u2013497 (2018).","journal-title":"Trends Microbiol."},{"key":"735_CR159","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jaci.2018.11.015","volume":"143","author":"AS Paller","year":"2019","unstructured":"Paller, A. S. et al. The microbiome in patients with atopic dermatitis. J. Allergy Clin. Immunol. 143, 26\u201335 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR160","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/jama.2019.19602","volume":"323","author":"CP Harkins","year":"2019","unstructured":"Harkins, C. P., Kong, H. H. & Segre, J. A. Manipulating the human microbiome to manage disease. J. Am. Med. Assoc. 323, 303\u2013304 (2019).","journal-title":"J. Am. Med. Assoc."},{"key":"735_CR161","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201900322","volume":"15","author":"EH Tham","year":"2020","unstructured":"Tham, E. H., Koh, E., Common, J. E. A. & Hwang, I. Y. Biotherapeutic approaches in atopic dermatitis. Biotechnol. J. 15, e1900322 (2020).","journal-title":"Biotechnol. J."},{"key":"735_CR162","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/d41573-019-00122-8","volume":"18","author":"M Cully","year":"2019","unstructured":"Cully, M. Microbiome therapeutics go small molecule. Nat. Rev. Drug Discov. 18, 569\u2013572 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"735_CR163","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86955","volume":"1","author":"IA Myles","year":"2016","unstructured":"Myles, I. A. et al. Transplantation of human skin microbiota in models of atopic dermatitis. JCI Insight 1, e86955 (2016).","journal-title":"JCI Insight"},{"key":"735_CR164","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s41591-021-01256-2","volume":"27","author":"T Nakatsuji","year":"2021","unstructured":"Nakatsuji, T. et al. Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial. Nat. Med. 27, 700\u2013709 (2021).","journal-title":"Nat. Med."},{"key":"735_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93299-1","volume":"11","author":"D Maura","year":"2021","unstructured":"Maura, D., Elmekki, N. & Goddard, C. A. The ammonia oxidizing bacterium Nitrosomonas eutropha blocks T helper 2 cell polarization via the anti-inflammatory cytokine IL-10. Sci. Rep. 11, 14162 (2021).","journal-title":"Sci. Rep."},{"key":"735_CR166","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamadermatol.2021.1311","volume":"157","author":"T Nakatsuji","year":"2021","unstructured":"Nakatsuji, T. et al. Use of autologous bacteriotherapy to treat Staphylococcus aureus in patients with atopic dermatitis: a randomized double-blind clinical trial. JAMA Dermatol. 157, 978\u2013982 (2021).","journal-title":"JAMA Dermatol."},{"key":"735_CR167","doi-asserted-by":"publisher","first-page":"adv00163","DOI":"10.2340\/00015555-3513","volume":"100","author":"SJ Brown","year":"2020","unstructured":"Brown, S. J., Elias, M. S. & Bradley, M. Genetics in atopic dermatitis: historical perspective and future prospects. Acta Derm. Venereol. 100, adv00163 (2020).","journal-title":"Acta Derm. Venereol."},{"key":"735_CR168","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jaci.2014.08.005","volume":"134","author":"EL Simpson","year":"2014","unstructured":"Simpson, E. L. et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J. Allergy Clin. Immunol. 134, 818\u2013823 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR169","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaci.2014.07.060","volume":"134","author":"K Horimukai","year":"2014","unstructured":"Horimukai, K. et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J. Allergy Clin. Immunol. 134, 824\u2013830.e6 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR170","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.aller.2014.06.003","volume":"42","author":"BK Kvenshagen","year":"2014","unstructured":"Kvenshagen, B. K., Carlsen, K. H., Mowinckel, P., Berents, T. L. & Carlsen, K. C. Can early skin care normalise dry skin and possibly prevent atopic eczema? A pilot study in young infants. Allergol. Immunopathol. 42, 539\u2013543 (2014).","journal-title":"Allergol. Immunopathol."},{"key":"735_CR171","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0140-6736(19)32984-8","volume":"395","author":"JR Chalmers","year":"2020","unstructured":"Chalmers, J. R. et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet 395, 962\u2013972 (2020).","journal-title":"Lancet"},{"key":"735_CR172","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(19)32983-6","volume":"395","author":"HO Skjerven","year":"2020","unstructured":"Skjerven, H. O. et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet 395, 951\u2013961 (2020).","journal-title":"Lancet"},{"key":"735_CR173","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(19)33174-5","volume":"395","author":"KP Perrett","year":"2020","unstructured":"Perrett, K. P. & Peters, R. L. Emollients for prevention of atopic dermatitis in infancy. Lancet 395, 923\u2013924 (2020).","journal-title":"Lancet"},{"key":"735_CR174","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jaci.2012.02.036","volume":"129","author":"G Lack","year":"2012","unstructured":"Lack, G. Update on risk factors for food allergy. J. Allergy Clin. Immunol. 129, 1187\u20131197 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR175","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/pde.13452","volume":"35","author":"EC Siegfried","year":"2018","unstructured":"Siegfried, E. C. et al. Developing drugs for treatment of atopic dermatitis in children (\u22653 months to <18 years of age): draft guidance for industry. Pediatr. Dermatol. 35, 303\u2013322 (2018).","journal-title":"Pediatr. Dermatol."},{"key":"735_CR176","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/pde.12867","volume":"33","author":"L Schneider","year":"2016","unstructured":"Schneider, L. et al. Study of the atopic march: development of atopic comorbidities. Pediatr. Dermatol. 33, 388\u2013398 (2016).","journal-title":"Pediatr. Dermatol."},{"key":"735_CR177","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.chembiol.2014.09.001","volume":"21","author":"MR Arkin","year":"2014","unstructured":"Arkin, M. R., Tang, Y. & Wells, J. A. Small-molecule inhibitors of protein\u2013protein interactions: progressing toward the reality. Chem. Biol. 21, 1102\u20131114 (2014).","journal-title":"Chem. Biol."},{"key":"735_CR178","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nrd.2016.29","volume":"15","author":"DE Scott","year":"2016","unstructured":"Scott, D. E., Bayly, A. R., Abell, C. & Skidmore, J. Small molecules, big targets: drug discovery faces the protein\u2013protein interaction challenge. Nat. Rev. Drug Discov. 15, 533\u2013550 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"735_CR179","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2174\/1568026618666180801092839","volume":"18","author":"S Majumdar","year":"2018","unstructured":"Majumdar, S., Ghosh, A. & Saha, S. Modulating interleukins and their receptors interactions with small chemicals using in silico approach for asthma. Curr. Top. Med. Chem. 18, 1123\u20131134 (2018).","journal-title":"Curr. Top. Med. Chem."},{"key":"735_CR180","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/jid.2012.239","volume":"133","author":"JM Leyva-Castillo","year":"2013","unstructured":"Leyva-Castillo, J. M., Hener, P., Jiang, H. & Li, M. TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice. J. Invest. Dermatol. 133, 154\u2013163 (2013).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR181","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40259-021-00490-x","volume":"35","author":"N Yang","year":"2021","unstructured":"Yang, N., Chen, Z., Zhang, X. & Shi, Y. Novel targeted biological agents for the treatment of atopic dermatitis. BioDrugs 35, 401\u2013415 (2021).","journal-title":"BioDrugs"},{"key":"735_CR182","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jaci.2022.08.015","volume":"150","author":"M Maurer","year":"2022","unstructured":"Maurer, M. et al. Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis. J. Allergy Clin. Immunol. 150, 1517\u20131524 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR183","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jaci.2022.10.009","volume":"150","author":"CFT Schuler","year":"2022","unstructured":"Schuler, C. F. T. & Gudjonsson, J. E. IL-33 antagonism does not improve chronic atopic dermatitis: what can we learn? J. Allergy Clin. Immunol. 150, 1410\u20131411 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR184","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1172\/JCI1647","volume":"101","author":"JM Spergel","year":"1998","unstructured":"Spergel, J. M. et al. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J. Clin. Invest. 101, 1614\u20131622 (1998).","journal-title":"J. Clin. Invest."},{"key":"735_CR185","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jaci.2011.01.031","volume":"127","author":"SJ Brown","year":"2011","unstructured":"Brown, S. J. et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J. Allergy Clin. Immunol. 127, 661\u2013667 (2011).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR186","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","volume":"401","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky, E. et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet 401, 204\u2013214 (2023).","journal-title":"Lancet"},{"key":"735_CR187","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.3390\/pharmaceutics14122753","volume":"14","author":"AM Le","year":"2022","unstructured":"Le, A. M. & Torres, T. OX40-OX40L inhibition for the treatment of atopic dermatitis \u2014 focus on rocatinlimab and amlitelimab. Pharmaceutics 14, 2753 (2022).","journal-title":"Pharmaceutics"},{"key":"735_CR188","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/all.13129","volume":"72","author":"LH Blom","year":"2017","unstructured":"Blom, L. H. et al. The immunoglobulin superfamily member CD200R identifies cells involved in type 2 immune responses. Allergy 72, 1081\u20131090 (2017).","journal-title":"Allergy"},{"key":"735_CR189","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3390\/ijms22041602","volume":"22","author":"K Kotwica-Mojzych","year":"2021","unstructured":"Kotwica-Mojzych, K., Jodlowska-Jedrych, B. & Mojzych, M. CD200:CD200R interactions and their importance in immunoregulation. Int. J. Mol. Sci. 22, 1602 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"735_CR190","doi-asserted-by":"publisher","first-page":"100103","DOI":"10.1016\/j.jtauto.2021.100103","volume":"4","author":"N Dixit","year":"2021","unstructured":"Dixit, N. et al. NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J. Transl. Autoimmun. 4, 100103 (2021).","journal-title":"J. Transl. Autoimmun."},{"key":"735_CR191","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jaci.2015.05.049","volume":"136","author":"T Czarnowicki","year":"2015","unstructured":"Czarnowicki, T. et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2\/TH1 cell imbalance, whereas adults acquire CLA(+) TH22\/TC22 cell subsets. J. Allergy Clin. Immunol. 136, 941\u2013951.e943 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR192","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","volume":"138","author":"H Esaki","year":"2016","unstructured":"Esaki, H. et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J. Allergy Clin. Immunol. 138, 1639\u20131651 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR193","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.anai.2018.11.025","volume":"122","author":"PM Brunner","year":"2019","unstructured":"Brunner, P. M. et al. Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients. Ann. Allergy Asthma Immunol. 122, 318\u2013330.e3 (2019).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"735_CR194","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jaci.2019.01.015","volume":"144","author":"L Zhou","year":"2019","unstructured":"Zhou, L. et al. Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. J. Allergy Clin. Immunol. 144, 144\u2013156 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR195","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber, T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy 75, 54\u201362 (2020).","journal-title":"Allergy"},{"key":"735_CR196","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cyto.2015.05.008","volume":"75","author":"K Bao","year":"2015","unstructured":"Bao, K. & Reinhardt, R. L. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine 75, 25\u201337 (2015).","journal-title":"Cytokine"},{"key":"735_CR197","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","volume":"143","author":"PM Brunner","year":"2019","unstructured":"Brunner, P. M. et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J. Allergy Clin. Immunol. 143, 142\u2013154 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR198","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jid.2021.07.155","volume":"142","author":"A Padhi","year":"2022","unstructured":"Padhi, A. et al. IL-22 downregulates peptidylarginine deiminase-1 in human keratinocytes: adding another piece to the IL-22 puzzle in epidermal barrier formation. J. Invest. Dermatol. 142, 333\u2013342.e6 (2022).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR199","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/jid.2014.51","volume":"134","author":"S Nakajima","year":"2014","unstructured":"Nakajima, S. et al. IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J. Invest. Dermatol. 134, 2122\u20132130 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR200","doi-asserted-by":"publisher","first-page":"707","DOI":"10.4049\/jimmunol.1602185","volume":"199","author":"A Floudas","year":"2017","unstructured":"Floudas, A. et al. IL-17 receptor a maintains and protects the skin barrier to prevent allergic skin inflammation. J. Immunol. 199, 707\u2013717 (2017).","journal-title":"J. Immunol."},{"key":"735_CR201","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/ACI.0000000000000658","volume":"20","author":"FA Topal","year":"2020","unstructured":"Topal, F. A., Zuberbier, T., Makris, M. P. & Hofmann, M. The role of IL-17, IL-23 and IL-31, IL-33 in allergic skin diseases. Curr. Opin. Allergy Clin. Immunol. 20, 367\u2013373 (2020).","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"735_CR202","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12047","volume":"11","author":"MA Hofmann","year":"2021","unstructured":"Hofmann, M. A. et al. Role of IL-17 in atopy \u2014 a systematic review. Clin. Transl. Allergy 11, e12047 (2021).","journal-title":"Clin. Transl. Allergy"},{"key":"735_CR203","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1111\/exd.14389","volume":"30","author":"JT Sims","year":"2021","unstructured":"Sims, J. T. et al. Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease. Exp. Dermatol. 30, 1650\u20131661 (2021).","journal-title":"Exp. Dermatol."},{"key":"735_CR204","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 16, 843\u2013862 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"735_CR205","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","volume":"58","author":"M Gadina","year":"2019","unstructured":"Gadina, M. et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology 58, i4\u2013i16 (2019).","journal-title":"Rheumatology"},{"key":"735_CR206","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka, Y., Luo, Y., O\u2019Shea, J. J. & Nakayamada, S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat. Rev. Rheumatol. 18, 133\u2013145 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"735_CR207","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.05.008","volume":"99","author":"K Ogawa","year":"2020","unstructured":"Ogawa, K. & Okada, Y. The current landscape of psoriasis genetics in 2020. J. Dermatol. Sci. 99, 2\u20138 (2020).","journal-title":"J. Dermatol. Sci."},{"key":"735_CR208","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.3390\/ijms23105518","volume":"23","author":"YC Tsai","year":"2022","unstructured":"Tsai, Y. C. & Tsai, T. F. Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes. Int. J. Mol. Sci. 23, 5518 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"735_CR209","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00438-021-01804-y","volume":"296","author":"Y Luo","year":"2021","unstructured":"Luo, Y. et al. Epigenetics in psoriasis: perspective of DNA methylation. Mol. Genet. Genom. 296, 1027\u20131040 (2021).","journal-title":"Mol. Genet. Genom."},{"key":"735_CR210","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/978-981-15-3449-2_8","volume":"1253","author":"S Shao","year":"2020","unstructured":"Shao, S. & Gudjonsson, J. E. Epigenetics of psoriasis. Adv. Exp. Med. Biol. 1253, 209\u2013221 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"735_CR211","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"JE Greb","year":"2016","unstructured":"Greb, J. E. et al. Psoriasis. Nat. Rev. Dis. Prim. 2, 16082 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"735_CR212","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","volume":"143","author":"N Dand","year":"2019","unstructured":"Dand, N. et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J. Allergy Clin. Immunol. 143, 2120\u20132130 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR213","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ng.311","volume":"41","author":"RP Nair","year":"2009","unstructured":"Nair, R. P. et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41, 199\u2013204 (2009).","journal-title":"Nat. Genet."},{"key":"735_CR214","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ng.2827","volume":"46","author":"H Tang","year":"2014","unstructured":"Tang, H. et al. A large-scale screen for coding variants predisposing to psoriasis. Nat. Genet. 46, 45\u201350 (2014).","journal-title":"Nat. Genet."},{"key":"735_CR215","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/511051","volume":"80","author":"M Cargill","year":"2007","unstructured":"Cargill, M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273\u2013290 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"735_CR216","doi-asserted-by":"publisher","first-page":"adv00030","DOI":"10.2340\/00015555-3384","volume":"100","author":"N Dand","year":"2020","unstructured":"Dand, N. et al. Psoriasis and genetics. Acta Derm. Venereol. 100, adv00030 (2020).","journal-title":"Acta Derm. Venereol."},{"key":"735_CR217","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","volume":"9","author":"MP Schon","year":"2018","unstructured":"Schon, M. P. & Erpenbeck, L. The interleukin-23\/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front. Immunol. 9, 1323 (2018).","journal-title":"Front. Immunol."},{"key":"735_CR218","doi-asserted-by":"publisher","first-page":"101520","DOI":"10.1016\/j.smim.2021.101520","volume":"58","author":"C Bridgewood","year":"2021","unstructured":"Bridgewood, C., Newton, D., Bragazzi, N., Wittmann, M. & McGonagle, D. Unexpected connections of the IL-23\/IL-17 and IL-4\/IL-13 cytokine axes in inflammatory arthritis and enthesitis. Semin. Immunol. 58, 101520 (2021).","journal-title":"Semin. Immunol."},{"key":"735_CR219","doi-asserted-by":"publisher","first-page":"621956","DOI":"10.3389\/fimmu.2021.621956","volume":"12","author":"H Bugaut","year":"2021","unstructured":"Bugaut, H. & Aractingi, S. Major role of the IL17\/23 axis in psoriasis supports the development of new targeted therapies. Front. Immunol. 12, 621956 (2021).","journal-title":"Front. Immunol."},{"key":"735_CR220","doi-asserted-by":"crossref","first-page":"204062232110378","DOI":"10.1177\/20406223211037846","volume":"12","author":"H Iznardo","year":"2021","unstructured":"Iznardo, H. & Puig, L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Ther. Adv. Chron. Dis. 12, 20406223211037846 (2021).","journal-title":"Ther. Adv. Chron. Dis."},{"key":"735_CR221","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt, A. & Chiricozzi, A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin. Rev. Allergy Immunol. 55, 379\u2013390 (2018).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"735_CR222","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","volume":"192","author":"S Cheuk","year":"2014","unstructured":"Cheuk, S. et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J. Immunol. 192, 3111\u20133120 (2014).","journal-title":"J. Immunol."},{"key":"735_CR223","doi-asserted-by":"publisher","first-page":"652191","DOI":"10.3389\/fimmu.2021.652191","volume":"12","author":"GE Ryan","year":"2021","unstructured":"Ryan, G. E., Harris, J. E. & Richmond, J. M. Resident memory T cells in autoimmune skin diseases. Front. Immunol. 12, 652191 (2021).","journal-title":"Front. Immunol."},{"key":"735_CR224","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1172\/JCI93396","volume":"127","author":"TR Matos","year":"2017","unstructured":"Matos, T. R. et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing alphabeta T cell clones. J. Clin. Invest. 127, 4031\u20134041 (2017).","journal-title":"J. Clin. Invest."},{"key":"735_CR225","doi-asserted-by":"publisher","first-page":"618897","DOI":"10.3389\/fimmu.2020.618897","volume":"11","author":"Y Tokura","year":"2020","unstructured":"Tokura, Y., Phadungsaksawasdi, P., Kurihara, K., Fujiyama, T. & Honda, T. Pathophysiology of skin resident memory T cells. Front. Immunol. 11, 618897 (2020).","journal-title":"Front. Immunol."},{"key":"735_CR226","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/jid.2010.280","volume":"131","author":"M Suarez-Farinas","year":"2011","unstructured":"Suarez-Farinas, M., Fuentes-Duculan, J., Lowes, M. A. & Krueger, J. G. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J. Invest. Dermatol. 131, 391\u2013400 (2011).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR227","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/bjd.20827","volume":"186","author":"R Oliver","year":"2022","unstructured":"Oliver, R. et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br. J. Dermatol. 186, 652\u2013663 (2022).","journal-title":"Br. J. Dermatol."},{"key":"735_CR228","doi-asserted-by":"publisher","first-page":"eabq3254","DOI":"10.1126\/sciimmunol.abq3254","volume":"7","author":"SK Whitley","year":"2022","unstructured":"Whitley, S. K. et al. Local IL-23 is required for proliferation and retention of skin-resident memory T(H)17 cells. Sci. Immunol. 7, eabq3254 (2022).","journal-title":"Sci. Immunol."},{"key":"735_CR229","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nm1605","volume":"13","author":"C Conrad","year":"2007","unstructured":"Conrad, C. et al. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat. Med. 13, 836\u2013842 (2007).","journal-title":"Nat. Med."},{"key":"735_CR230","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jid.2020.11.025","volume":"141","author":"MT Patrick","year":"2021","unstructured":"Patrick, M. T. et al. Causal relationship and shared genetic loci between psoriasis and type 2 diabetes through trans-disease meta-analysis. J. Invest. Dermatol. 141, 1493\u20131502 (2021).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR231","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/jdv.14313","volume":"31","author":"KA Papp","year":"2017","unstructured":"Papp, K. A., Gooderham, M. J., Girard, G., Raman, M. & Strout, V. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 31, 1324\u20131332 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"735_CR232","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jid.2022.01.014","volume":"142","author":"PC van de Kerkhof","year":"2022","unstructured":"van de Kerkhof, P. C. From empirical to pathogenesis-based treatments for psoriasis. J. Invest. Dermatol. 142, 1778\u20131785 (2022).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR233","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","volume":"139","author":"KB Gordon","year":"2019","unstructured":"Gordon, K. B. et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. J. Invest. Dermatol. 139, 2437\u20132446.e1 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR234","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","volume":"172","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt, A. et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br. J. Dermatol. 172, 484\u2013493 (2015).","journal-title":"Br. J. Dermatol."},{"key":"735_CR235","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober, B. et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J. Am. Acad. Dermatol. 88, 40\u201351 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR236","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1056\/NEJMoa1104200","volume":"365","author":"S Eyerich","year":"2011","unstructured":"Eyerich, S. et al. Mutual antagonism of T cells causing psoriasis and atopic eczema. N. Engl. J. Med. 365, 231\u2013238 (2011).","journal-title":"N. Engl. J. Med."},{"key":"735_CR237","doi-asserted-by":"crossref","first-page":"2050313X2090456","DOI":"10.1177\/2050313X20904561","volume":"8","author":"R Bose","year":"2020","unstructured":"Bose, R. & Beecker, J. Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: a case report. SAGE Open. Med. Case Rep. 8, 2050313X20904561 (2020).","journal-title":"SAGE Open. Med. Case Rep."},{"key":"735_CR238","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/jdv.16246","volume":"34","author":"A Al-Janabi","year":"2020","unstructured":"Al-Janabi, A. et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J. Eur. Acad. Dermatol. Venereol. 34, 1440\u20131448 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"735_CR239","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jaad.2019.08.023","volume":"82","author":"JN Cohen","year":"2020","unstructured":"Cohen, J. N., Bowman, S., Laszik, Z. G. & North, J. P. Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: a retrospective study of T helper type 2 and 17 subsets, interleukin 36, and beta-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor alpha inhibitor-associated dermatitis. J. Am. Acad. Dermatol. 82, 430\u2013439 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR240","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","volume":"87","author":"B Strober","year":"2022","unstructured":"Strober, B. et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J. Am. Acad. Dermatol. 87, 800\u2013806 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR241","doi-asserted-by":"publisher","first-page":"B26","DOI":"10.1016\/j.jid.2022.05.1011","volume":"142","author":"N Mooney","year":"2022","unstructured":"Mooney, N. et al. Tapinarof inhibits the formation, cytokine production, and persistence of resident memory T cells in vitro. J. Investig. Dermatol. 142, B26 (2022).","journal-title":"J. Investig. Dermatol."},{"key":"735_CR242","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/jdv.16966","volume":"35","author":"NM Golbari","year":"2021","unstructured":"Golbari, N. M. et al. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J. Eur. Acad. Dermatol. Venereol. 35, 417\u2013421 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"735_CR243","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/09546634.2019.1626973","volume":"31","author":"A Pinter","year":"2020","unstructured":"Pinter, A., Gerdes, S., Papavassilis, C. & Reinhardt, M. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J. Dermatol. Treat. 31, 769\u2013775 (2020).","journal-title":"J. Dermatol. Treat."},{"key":"735_CR244","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/09546634.2014.880396","volume":"26","author":"G Girolomoni","year":"2015","unstructured":"Girolomoni, G. et al. Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper. J. Dermatol. Treat. 26, 103\u2013112 (2015).","journal-title":"J. Dermatol. Treat."},{"key":"735_CR245","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","volume":"43","author":"VP Nell","year":"2004","unstructured":"Nell, V. P. et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43, 906\u2013914 (2004).","journal-title":"Rheumatology"},{"key":"735_CR246","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.rdc.2005.07.001","volume":"31","author":"MA Quinn","year":"2005","unstructured":"Quinn, M. A. & Cox, S. The evidence for early intervention. Rheum. Dis. Clin. North Am. 31, 575\u2013589 (2005).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"735_CR247","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","volume":"43","author":"JJ Anderson","year":"2000","unstructured":"Anderson, J. J., Wells, G., Verhoeven, A. C. & Felson, D. T. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 43, 22\u201329 (2000).","journal-title":"Arthritis Rheum."},{"key":"735_CR248","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","volume":"371","author":"G D\u2019Haens","year":"2008","unstructured":"D\u2019Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial. Lancet 371, 660\u2013667 (2008).","journal-title":"Lancet"},{"key":"735_CR249","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/ana.21757","volume":"66","author":"M Trojano","year":"2009","unstructured":"Trojano, M. et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann. Neurol. 66, 513\u2013520 (2009).","journal-title":"Ann. Neurol."},{"key":"735_CR250","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049822","volume":"11","author":"K Eyerich","year":"2021","unstructured":"Eyerich, K. et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open 11, e049822 (2021).","journal-title":"BMJ Open"},{"key":"735_CR251","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.41239","volume":"74","author":"D Simon","year":"2022","unstructured":"Simon, D. et al. Association of structural entheseal lesions with an increased risk of progression from psoriasis to psoriatic arthritis. Arthritis Rheumatol. 74, 253\u2013262 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"735_CR252","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/ATVBAHA.118.312246","volume":"39","author":"MS Garshick","year":"2019","unstructured":"Garshick, M. S. et al. Inflammasome signaling and impaired vascular health in psoriasis. Arterioscler. Thromb. Vasc. Biol. 39, 787\u2013798 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"735_CR253","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1080\/09546634.2019.1605142","volume":"31","author":"A Gottlieb","year":"2020","unstructured":"Gottlieb, A. & Merola, J. F. Psoriatic arthritis for dermatologists. J. Dermatol. Treat. 31, 662\u2013679 (2020).","journal-title":"J. Dermatol. Treat."},{"key":"735_CR254","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/PTT.S323300","volume":"12","author":"P Gisondi","year":"2022","unstructured":"Gisondi, P. et al. Reducing the risk of developing psoriatic arthritis in patients with psoriasis. Psoriasis 12, 213\u2013220 (2022).","journal-title":"Psoriasis"},{"key":"735_CR255","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/art.41946","volume":"74","author":"YS Rosenthal","year":"2022","unstructured":"Rosenthal, Y. S., Schwartz, N., Sagy, I. & Pavlovsky, L. Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case\u2013control study. Arthritis Rheumatol. 74, 237\u2013243 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"735_CR256","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","volume":"81","author":"ML Acosta Felquer","year":"2022","unstructured":"Acosta Felquer, M. L. et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann. Rheum. Dis. 81, 74\u201379 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"735_CR257","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon, M., Gallagher, P. & FitzGerald, O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann. Rheum. Dis. 74, 1045\u20131050 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"735_CR258","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2230.1995.tb01274.x","volume":"20","author":"JD Creamer","year":"1995","unstructured":"Creamer, J. D. & Barker, J. N. Vascular proliferation and angiogenic factors in psoriasis. Clin. Exp. Dermatol. 20, 6\u20139 (1995).","journal-title":"Clin. Exp. Dermatol."},{"key":"735_CR259","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11883-021-00963-y","volume":"23","author":"B Weber","year":"2021","unstructured":"Weber, B. et al. Psoriasis and cardiovascular disease: novel mechanisms and evolving therapeutics. Curr. Atheroscler. Rep. 23, 67 (2021).","journal-title":"Curr. Atheroscler. Rep."},{"key":"735_CR260","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000121333","volume":"217","author":"AB Kimball","year":"2008","unstructured":"Kimball, A. B. et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001\u20132002. Dermatology 217, 27\u201337 (2008).","journal-title":"Dermatology"},{"key":"735_CR261","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","volume":"77","author":"MS Garshick","year":"2021","unstructured":"Garshick, M. S., Ward, N. L., Krueger, J. G. & Berger, J. S. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J. Am. Coll. Cardiol. 77, 1670\u20131680 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"735_CR262","first-page":"273","volume":"3","author":"S Rose","year":"2013","unstructured":"Rose, S. et al. A comparison of vascular inflammation in psoriasis, rheumatoid arthritis, and healthy subjects by FDG-PET\/CT: a pilot study. Am. J. Cardiovasc. Dis. 3, 273\u2013278 (2013).","journal-title":"Am. J. Cardiovasc. Dis."},{"key":"735_CR263","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.017417","volume":"9","author":"W Zhou","year":"2020","unstructured":"Zhou, W. et al. Association among noncalcified coronary burden, fractional flow reserve, and myocardial injury in psoriasis. J. Am. Heart Assoc. 9, e017417 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"735_CR264","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/jdv.13152","volume":"30","author":"O Ahlehoff","year":"2016","unstructured":"Ahlehoff, O. et al. Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study. J. Eur. Acad. Dermatol. Venereol. 30, 819\u2013823 (2016).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"735_CR265","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaad.2016.07.042","volume":"76","author":"JJ Wu","year":"2017","unstructured":"Wu, J. J. et al. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. J. Am. Acad. Dermatol. 76, 81\u201390 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR266","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1001\/jama.2013.4695","volume":"309","author":"AW Armstrong","year":"2013","unstructured":"Armstrong, A. W. Do TNF inhibitors reduce the risk of myocardial infarction in psoriasis patients? J. Am. Med. Assoc. 309, 2043\u20132044 (2013).","journal-title":"J. Am. Med. Assoc."},{"key":"735_CR267","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand, J. M. et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial). J. Invest. Dermatol. 140, 85\u201393.e2 (2020).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR268","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.jid.2021.07.190","volume":"142","author":"MS Garshick","year":"2022","unstructured":"Garshick, M. S. et al. A randomized open-label clinical trial of lipid-lowering therapy in psoriasis to reduce vascular endothelial inflammation. J. Invest. Dermatol. 142, 1749\u20131752.e4 (2022).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR269","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1001\/jamadermatol.2021.4723","volume":"158","author":"MS Garshick","year":"2022","unstructured":"Garshick, M. S. & Berger, J. S. Psoriasis and cardiovascular disease \u2014 an ounce of prevention is worth a pound of cure. JAMA Dermatol. 158, 239\u2013241 (2022).","journal-title":"JAMA Dermatol."},{"key":"735_CR270","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jaci.2017.10.046","volume":"141","author":"N Dyjack","year":"2018","unstructured":"Dyjack, N. et al. Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2-high atopic dermatitis disease endotype. J. Allergy Clin. Immunol. 141, 1298\u20131309 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR271","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","volume":"137","author":"B Ungar","year":"2017","unstructured":"Ungar, B. et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J. Invest. Dermatol. 137, 603\u2013613 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR272","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jaci.2020.05.048","volume":"147","author":"H He","year":"2021","unstructured":"He, H. et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J. Allergy Clin. Immunol. 147, 199\u2013212 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR273","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jaip.2021.02.027","volume":"9","author":"L Maintz","year":"2021","unstructured":"Maintz, L., Bieber, T., Bissonnette, R. & Jack, C. Measuring atopic dermatitis disease severity: the potential for electronic tools to benefit clinical care. J. Allergy Clin. Immunol. Pract. 9, 1473\u20131486.e2 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"735_CR274","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gut.2009.187120","volume":"59","author":"L Peyrin-Biroulet","year":"2010","unstructured":"Peyrin-Biroulet, L., Loftus, E. V. Jr, Colombel, J. F. & Sandborn, W. J. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut 59, 141\u2013147 (2010).","journal-title":"Gut"},{"key":"735_CR275","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000342732","volume":"30","author":"JF Colombel","year":"2012","unstructured":"Colombel, J. F., Louis, E., Peyrin-Biroulet, L., Sandborn, W. J. & Panaccione, R. Deep remission: a new concept? Dig. Dis. 30, 107\u2013111 (2012).","journal-title":"Dig. Dis."},{"key":"735_CR276","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/MOG.0b013e3283622914","volume":"29","author":"PB Allen","year":"2013","unstructured":"Allen, P. B. & Peyrin-Biroulet, L. Moving towards disease modification in inflammatory bowel disease therapy. Curr. Opin. Gastroenterol. 29, 397\u2013404 (2013).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"735_CR277","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.cgh.2012.06.011","volume":"10","author":"SB Hanauer","year":"2012","unstructured":"Hanauer, S. B. Disease modification in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 10, 954\u2013955 (2012).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"735_CR278","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.det.2017.02.003","volume":"35","author":"K Abuabara","year":"2017","unstructured":"Abuabara, K., Margolis, D. J. & Langan, S. M. The long-term course of atopic dermatitis. Dermatol. Clin. 35, 291\u2013297 (2017).","journal-title":"Dermatol. Clin."},{"key":"735_CR279","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.jaad.2019.05.016","volume":"81","author":"J Wan","year":"2019","unstructured":"Wan, J., Mitra, N., Hoffstad, O. J., Yan, A. C. & Margolis, D. J. Longitudinal atopic dermatitis control and persistence vary with timing of disease onset in children: a cohort study. J. Am. Acad. Dermatol. 81, 1292\u20131299 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR280","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1111\/all.14194","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber, T. et al. Unraveling the complexity of atopic dermatitis: the CK-CARE approach toward precision medicine. Allergy 75, 2936\u20132938 (2020).","journal-title":"Allergy"},{"key":"735_CR281","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jaci.2017.03.023","volume":"140","author":"JL Thijs","year":"2017","unstructured":"Thijs, J. L. et al. Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis. J. Allergy Clin. Immunol. 140, 730\u2013737 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR282","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/14712598.2019.1583204","volume":"19","author":"J van der Schaft","year":"2019","unstructured":"van der Schaft, J., Thijs, J. L., Garritsen, F. M., Balak, D. & de Bruin-Weller, M. S. Towards personalized treatment in atopic dermatitis. Exp. Opin. Biol. Ther. 19, 469\u2013476 (2019).","journal-title":"Exp. Opin. Biol. Ther."},{"key":"735_CR283","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/exd.14582","volume":"31","author":"M Koschitzky","year":"2022","unstructured":"Koschitzky, M. et al. Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris. Exp. Dermatol. 31, 1341\u20131351 (2022).","journal-title":"Exp. Dermatol."},{"key":"735_CR284","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1001\/jamadermatol.2019.1783","volume":"155","author":"T Tsakok","year":"2019","unstructured":"Tsakok, T. et al. Association of serum ustekinumab levels with clinical response in psoriasis. JAMA Dermatol. 155, 1235\u20131243 (2019).","journal-title":"JAMA Dermatol."},{"key":"735_CR285","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jid.2018.04.041","volume":"139","author":"AC Foulkes","year":"2019","unstructured":"Foulkes, A. C. et al. A framework for multi-omic prediction of treatment response to biologic therapy for psoriasis. J. Invest. Dermatol. 139, 100\u2013107 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR286","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ced.13228","volume":"43","author":"YH Lee","year":"2018","unstructured":"Lee, Y. H. & Song, G. G. Association between circulating prolactin levels and psoriasis and its correlation with disease severity: a meta-analysis. Clin. Exp. Dermatol. 43, 27\u201335 (2018).","journal-title":"Clin. Exp. Dermatol."},{"key":"735_CR287","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jaci.2018.10.033","volume":"143","author":"K Eyerich","year":"2019","unstructured":"Eyerich, K. et al. Human and computational models of atopic dermatitis: a review and perspectives by an expert panel of the International Eczema Council. J. Allergy Clin. Immunol. 143, 36\u201345 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"735_CR288","doi-asserted-by":"publisher","first-page":"1002629","DOI":"10.3389\/fimmu.2022.1002629","volume":"13","author":"S Vetrano","year":"2022","unstructured":"Vetrano, S. et al. ImmUniverse Consortium: multi-omics integrative approach in personalized medicine for immune-mediated inflammatory diseases. Front. Immunol. 13, 1002629 (2022).","journal-title":"Front. Immunol."},{"key":"735_CR289","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/all.15578","volume":"78","author":"C Broderick","year":"2023","unstructured":"Broderick, C. et al. Biomarkers associated with the development of comorbidities in patients with atopic dermatitis: a systematic review. Allergy 78, 84\u2013120 (2023).","journal-title":"Allergy"},{"key":"735_CR290","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/jdv.18178","volume":"36","author":"S Ziehfreund","year":"2022","unstructured":"Ziehfreund, S. et al. Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021 \u2014 a two-round Delphi survey among international experts. J. Eur. Acad. Dermatol. Venereol. 36, 1467\u20131476 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"735_CR291","unstructured":"Lee, J. W., Wu, Y. & Wang, J. Fit-for-purpose method validation and assays for biomarker characterization to support drug development. in Biomarkers in Drug Development (eds Bleavins, M. R., Carini, C., Jurima-Romet, M. & Rahbari, R.) 187\u2013213 (Wiley, 2010)."},{"key":"735_CR292","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/j.1398-9995.2012.02845.x","volume":"67","author":"T Bieber","year":"2012","unstructured":"Bieber, T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy 67, 1475\u20131482 (2012).","journal-title":"Allergy"},{"key":"735_CR293","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/2475530320950267","volume":"5","author":"K Yu","year":"2020","unstructured":"Yu, K., Syed, M. N., Bernardis, E. & Gelfand, J. M. Machine learning applications in the evaluation and management of psoriasis: a systematic review. J. Psoriasis Psoriatic Arthritis 5, 147\u2013159 (2020).","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"735_CR294","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06672-6","volume":"9","author":"MT Patrick","year":"2018","unstructured":"Patrick, M. T. et al. Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nat. Commun. 9, 4178 (2018).","journal-title":"Nat. Commun."},{"key":"735_CR295","doi-asserted-by":"publisher","DOI":"10.1038\/srep19918","volume":"6","author":"ML Clausen","year":"2016","unstructured":"Clausen, M. L., Slotved, H. C., Krogfelt, K. A. & Agner, T. Tape stripping technique for stratum corneum protein analysis. Sci. Rep. 6, 19918 (2016).","journal-title":"Sci. Rep."},{"key":"735_CR296","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1111\/all.14842","volume":"76","author":"AO Rinaldi","year":"2021","unstructured":"Rinaldi, A. O. et al. Electrical impedance spectroscopy for the characterization of skin barrier in atopic dermatitis. Allergy 76, 3066\u20133079 (2021).","journal-title":"Allergy"},{"key":"735_CR297","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/all.15518","volume":"78","author":"MR Rinnov","year":"2023","unstructured":"Rinnov, M. R. et al. Skin biomarkers predict development of atopic dermatitis in infancy. Allergy 78, 791\u2013802 (2023).","journal-title":"Allergy"},{"key":"735_CR298","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/jid.2011.92","volume":"131","author":"DP Kelsell","year":"2011","unstructured":"Kelsell, D. P. & Byrne, C. SNPing at the epidermal barrier. J. Invest. Dermatol. 131, 1593\u20131595 (2011).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR299","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59627-7","volume":"10","author":"SP Smieszek","year":"2020","unstructured":"Smieszek, S. P. et al. Correlation of age-of-onset of atopic dermatitis with filaggrin loss-of-function variant status. Sci. Rep. 10, 2721 (2020).","journal-title":"Sci. Rep."},{"key":"735_CR300","first-page":"265","volume":"10","author":"E Kothekar","year":"2020","unstructured":"Kothekar, E. et al. Utility of FDG-PET\/CT in clinical psoriasis grading: the PET-PASI scoring system. Am. J. Nucl. Med. Mol. Imaging 10, 265\u2013271 (2020).","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"735_CR301","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.semnuclmed.2020.08.003","volume":"51","author":"R Seifert","year":"2021","unstructured":"Seifert, R., Weber, M., Kocakavuk, E., Rischpler, C. & Kersting, D. Artificial intelligence and machine learning in nuclear medicine: future perspectives. Semin. Nucl. Med. 51, 170\u2013177 (2021).","journal-title":"Semin. Nucl. Med."},{"key":"735_CR302","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41591-021-01614-0","volume":"28","author":"P Rajpurkar","year":"2022","unstructured":"Rajpurkar, P., Chen, E., Banerjee, O. & Topol, E. J. AI in health and medicine. Nat. Med. 28, 31\u201338 (2022).","journal-title":"Nat. Med."},{"key":"735_CR303","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2020.10.094","volume":"84","author":"YA Elnabawi","year":"2021","unstructured":"Elnabawi, Y. A. et al. CCL20 in psoriasis: a potential biomarker of disease severity, inflammation, and impaired vascular health. J. Am. Acad. Dermatol. 84, 913\u2013920 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR304","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jid.2020.05.115","volume":"141","author":"MS Garshick","year":"2021","unstructured":"Garshick, M. S. et al. Characterization of PCSK9 in the blood and skin of psoriasis. J. Invest. Dermatol. 141, 308\u2013315 (2021).","journal-title":"J. Invest. Dermatol."},{"key":"735_CR305","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11926-020-00891-x","volume":"22","author":"A Zabotti","year":"2020","unstructured":"Zabotti, A., Tinazzi, I., Aydin, S. Z. & McGonagle, D. From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention. Curr. Rheumatol. Rep. 22, 24 (2020).","journal-title":"Curr. Rheumatol. Rep."},{"key":"735_CR306","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.semarthrit.2010.05.009","volume":"40","author":"M Gutierrez","year":"2011","unstructured":"Gutierrez, M. et al. Subclinical entheseal involvement in patients with psoriasis: an ultrasound study. Semin. Arthritis Rheum. 40, 407\u2013412 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"735_CR307","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4103\/idoj.IDOJ_446_18","volume":"11","author":"K Vyas","year":"2020","unstructured":"Vyas, K. et al. Sonographic evaluation of subclinical enthesopathy in patients of chronic plaque psoriasis. Indian. Dermatol. Online J. 11, 580\u2013585 (2020).","journal-title":"Indian. Dermatol. Online J."},{"key":"735_CR308","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren, J. et al. Tezepelumab in adults with uncontrolled asthma. N. Engl. J. Med. 377, 936\u2013946 (2017).","journal-title":"N. Engl. J. Med."},{"key":"735_CR309","first-page":"89","volume":"21","author":"A Mullard","year":"2022","unstructured":"Mullard, A. FDA approves first-in-class TSLP-targeted antibody for severe asthma. Nat. Rev. Drug Discov. 21, 89 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"735_CR310","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","volume":"80","author":"EL Simpson","year":"2019","unstructured":"Simpson, E. L. et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J. Am. Acad. Dermatol. 80, 1013\u20131021 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR311","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1084\/jem.20051745","volume":"203","author":"YJ Liu","year":"2006","unstructured":"Liu, Y. J. Thymic stromal lymphopoietin: master switch for allergic inflammation. J. Exp. Med. 203, 269\u2013273 (2006).","journal-title":"J. Exp. Med."},{"key":"735_CR312","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1073\/pnas.0812668106","volume":"106","author":"Z Zhang","year":"2009","unstructured":"Zhang, Z. et al. Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc. Natl Acad. Sci. USA 106, 1536\u20131541 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"735_CR313","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.3389\/fimmu.2020.01907","volume":"11","author":"L Yang","year":"2020","unstructured":"Yang, L., Fu, J. & Zhou, Y. Research progress in atopic march. Front. Immunol. 11, 1907 (2020).","journal-title":"Front. Immunol."},{"key":"735_CR314","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","volume":"74","author":"EL Simpson","year":"2016","unstructured":"Simpson, E. L. et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J. Am. Acad. Dermatol. 74, 491\u2013498 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"735_CR315","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa066886","volume":"358","author":"AS Paller","year":"2008","unstructured":"Paller, A. S. et al. Etanercept treatment for children and adolescents with plaque psoriasis. N. Engl. J. Med. 358, 241\u2013251 (2008).","journal-title":"N. Engl. J. Med."},{"key":"735_CR316","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fmed.2019.00223","volume":"6","author":"AV Morant","year":"2019","unstructured":"Morant, A. V., Jagalski, V. & Vestergaard, H. T. Labeling of disease-modifying therapies for neurodegenerative disorders. Front. Med. 6, 223 (2019).","journal-title":"Front. Med."},{"key":"735_CR317","doi-asserted-by":"publisher","first-page":"631584","DOI":"10.3389\/fphar.2021.631584","volume":"12","author":"D Laifenfeld","year":"2021","unstructured":"Laifenfeld, D. et al. Emulated clinical trials from longitudinal real-world data efficiently identify candidates for neurological disease modification: examples from Parkinson\u2019s disease. Front. Pharmacol. 12, 631584 (2021).","journal-title":"Front. Pharmacol."},{"key":"735_CR318","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/pds.5222","volume":"30","author":"JM Franklin","year":"2021","unstructured":"Franklin, J. M., Liaw, K. L., Iyasu, S., Critchlow, C. W. & Dreyer, N. A. Real-world evidence to support regulatory decision making: new or expanded medical product indications. Pharmacoepidemiol. Drug Saf. 30, 685\u2013693 (2021).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"735_CR319","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/BOT.0000000000002039","volume":"35","author":"S De","year":"2021","unstructured":"De, S., Larson, L., Kelly, K., Hanson, B. & Mack, C. D. Leveraging real-world evidence: a paradigm shift in regulation. J. Orthop. Trauma. 35, S13\u2013S16 (2021).","journal-title":"J. Orthop. Trauma."},{"key":"735_CR320","doi-asserted-by":"publisher","first-page":"e641","DOI":"10.1016\/S2666-7568(22)00214-8","volume":"3","author":"NA Dreyer","year":"2022","unstructured":"Dreyer, N. A. Strengthening evidence-based medicine with real-world evidence. Lancet Healthy Longev. 3, e641\u2013e642 (2022).","journal-title":"Lancet Healthy Longev."},{"key":"735_CR321","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/bjd.21794","volume":"187","author":"D Stolzl","year":"2022","unstructured":"Stolzl, D. et al. Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry. Br. J. Dermatol. 187, 1022\u20131024 (2022).","journal-title":"Br. J. Dermatol."},{"key":"735_CR322","unstructured":"FDA. Draft guidance for industry. Indications and usage section of labeling for human prescription drug and biological products \u2014 content and format (2018)."},{"key":"735_CR323","unstructured":"European Commission. Notice to applicants. A guideline on Summary of Product Characteristics (SmPC) (2009)."}],"updated-by":[{"DOI":"10.1038\/s41573-023-00790-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000}}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00735-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00735-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00735-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T02:29:06Z","timestamp":1729736946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00735-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":323,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["735"],"URL":"https:\/\/doi.org\/10.1038\/s41573-023-00735-0","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41573-023-00790-7","asserted-by":"object"}]},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"assertion":[{"value":"5 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41573-023-00790-7","URL":"https:\/\/doi.org\/10.1038\/s41573-023-00790-7","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.B. was speaker and\/or consultant and\/or investigator for AbbVie, Affibody, Almirall, Amagma, AnaptysBio, AOBiom, Arena, Aristea, Asana Biosciences, ASLAN Pharma, Bayer Health, BioVerSys, B\u00f6hringer-Ingelheim, Bristol-Myers Squibb, Connect Pharma, Daichi-Sanyko, Dermavant, DIECE Therapeutics, Domain Therapeutics, DS Pharma, EQRx, Evelo, Galderma, Galapagos, Glenmark, GSK, Incyte, Innovaderm, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L\u2019Or\u00e9al, MSD, Medac, Micreos, Nektar, Novartis, Numab, OM-Pharma, Overtone, Pfizer, Pierre Fabre, Q32bio, RAPT, Sanofi\/Regeneron, UCB and Union Therapeutics. He is the founder and chairman of the board of the non-profit biotech \u2018Davos Biosciences\u2019 within the International K\u00fchne-Foundation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}